MEDIA STATEMENT

KING OF PRUSSIA, PA, June 12, 2019 – Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics, a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, issued the following statement regarding the recent introduction of the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 by United States Senators Johnny Isakson (R-GA) and Bob Casey (D-PA):

“The introduction of the DISARM Act of 2019 is an encouraging step toward addressing the extremely serious public health threat posed by antimicrobial resistance – sometimes called ‘superbugs’ – in the U.S. Most importantly, the Act will provide for additional payments under Medicare reimbursement for new antimicrobial drugs, which will help advocate appropriate use and support small biopharmaceutical companies, which are responsible for 80 percent of all antibiotic research and development.

“This issue should matter to every American. According to the Centers for Disease Control and Prevention, each year at least two million people get an antibiotic-resistant infection in this country. It’s estimated that, of these, more than 162,000 people die. That’s the equivalent of a jumbo jet crashing to the ground every single day of the year.
“Today, thanks to the Generating Antibiotic Incentives Now (GAIN) Act of 2012, there are strong regulatory incentives to support the development of new antibiotics. But spurring R&D has only gotten us part of the way there while current Medicare reimbursement unintentionally prevents the use of novel, innovative treatments. The introduction of the DISARM Act of 2019 is an important step to changing Medicare reimbursement policy for anti-infective drugs for the benefit of our nation’s health. We look forward to working with members of Congress and stakeholders across the antimicrobial community to ensure passage of this important legislation.”

For the full legislative text of the DISARM Act of 2019, click here:

About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics has two product candidates that are in late stage development: lefamulin, potentially the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP) and CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). For more information, please visit https://www.nabriva.com.

CONTACTS:
For Investors
Dave Garrett
Nabriva Therapeutics plc
david.garrett@nabriva.com
610-816-6657

For Media
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502